HYPOXPROBE

The development of hypoxia-activated probes for imaging and therapy

 Coordinatore THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

 Organization address address: University Offices, Wellington Square
city: OXFORD
postcode: OX1 2JD

contact info
Titolo: Mr.
Nome: Gill
Cognome: Wells
Email: send email
Telefono: +44 1865 289800
Fax: +44 1865 289801

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 231˙283 €
 EC contributo 231˙283 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2012-IIF
 Funding Scheme MC-IIF
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-11-01   -   2015-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

 Organization address address: University Offices, Wellington Square
city: OXFORD
postcode: OX1 2JD

contact info
Titolo: Mr.
Nome: Gill
Cognome: Wells
Email: send email
Telefono: +44 1865 289800
Fax: +44 1865 289801

UK (OXFORD) coordinator 231˙283.20

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

pimonidazole    transcription    interacting    crebbp    protein    tumour    activated    hypoxic    resolution    cellular    compound    release    fluorescent    imaging    tumours    oxygen    cells    alpha    hypoxia    binding    inhibitors    bromodomain    group    active   

 Obiettivo del progetto (Objective)

'Solid tumours contain hypoxic cells, which exist at a low oxygen tensions and are resistant to chemotherapy and radiotherapy. Although problematic for therapy, any quality that distinguishes tumour cells from healthy ones presents an opportunity for targeting therapies. We have begun developing prodrugs that selectively release inhibitors of cancer-related enzymes under hypoxia. In this project, we will develop hypoxia-activated inhibitors of the checkpoint kinase, Chk1, which is an important chemotherapeutic target. Allowing targeting of this compound to tumour cells. In addition, to enable imaging of hypoxic tumours we will develop novel hypoxia-activated fluorescent probes. The 2-nitroimidazole-based pimonidazole is a standard hypoxia-imaging agent. Pimonidazole binds cellular thiols under hypoxic conditions but the spatial resolution of imaging is poor. To improve the imaging resolution, we will develop a fluorogenic hypoxia-activated protecting group that will become fluorescent upon release of the active compound. This will provide a read-out of when and where the active compound is delivered, and fill also find application in the general imaging of hypoxia. We then aim to apply this technology to developing hypoxia-activated inhibitors of the cAMP response element binding protein binding protein (CREBBP) bromodomain. CREBBP is a histone acetyl transferase involved in regulating transcription; it has ~400 interacting protein partners making it a key node in the mammalian protein-protein interactome. One partner is hypoxia-inducible factor-1α (HIF-1α), which is a transcription factor that responds to changes in cellular oxygen levels. Given the large number of CREBBP interacting partners it is preferable to target the CREBBP bromodomain inhibitor using a hypoxia-activated group. In this way it will be possible to ascertain the role of the CREBBP bromodomain in hypoxic tumours.'

Altri progetti dello stesso programma (FP7-PEOPLE)

REEF FISH DIVERSITY (2010)

Diversity and community assembly in Caribbean reef fish

Read More  

CODE (2008)

Constraining Dark Energy: an observational study of the properties of dark energy and dark matter

Read More  

ADAPT (2013)

Assessment of dermal absorption of organic flame retardant chemicals using 3D-in vitro human skin models

Read More